An ink set includes a first ink containing the compound represented by formula (y-1) or its salt, a second ink containing one or two or more of the compound represented by formula (m-1) or its salt, the compound represented by formula (m-2) or its salt, a compound represented by formula (m-3) or its salt, and the compound represented by formula (m-4) or its salt, and a third ink containing one or two or more of a compound represented by formula (c-1) or its salt, the compound represented by formula (c-2) or its salt, the compound represented by formula (c-3) or its salt, a compound represented by formula (c-4) or its salt, and the compound represented by formula (c-5) or its salt. ##STR00001##

An ink set includes a first ink containing the compound represented by formula (y-1) or its salt, a second ink containing one or two or more of the compound represented by formula (m-1) or its salt, the compound represented by formula (m-2) or its salt, a compound represented by formula (m-3) or its salt, and the compound represented by formula (m-4) or its salt, and a third ink containing one or two or more of a compound represented by formula (c-1) or its salt, the compound represented by formula (c-2) or its salt, the compound represented by formula (c-3) or its salt, a compound represented by formula (c-4) or its salt, and the compound represented by formula (c-5) or its salt. ##STR00001##

An N-substituted triacetonediamine compound is produced by reacting 4-amino-2,2,6,6-tetramethylpiperidine or a derivative thereof with a carbonyl compound in a reductive amination.

An N-substituted triacetonediamine compound is produced by reacting 4-amino-2,2,6,6-tetramethylpiperidine or a derivative thereof with a carbonyl compound in a reductive amination.

The invention provides compounds of Formula (I), and their use in methods for treating or preventing a protozoan infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in the manufacture of a medicament for the treatment of a protozoan infection in a subject. The invention further provides a medical device when used in a method of treating or preventing a protozoan infection in a subject and to a medical device comprising the composition of the invention.

The invention provides compounds of Formula (I), and their use in methods for treating or preventing a protozoan infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in the manufacture of a medicament for the treatment of a protozoan infection in a subject. The invention further provides a medical device when used in a method of treating or preventing a protozoan infection in a subject and to a medical device comprising the composition of the invention.

Disclosed is method for treating cancer in a mammal, comprising administering to a mammal in need thereof a compound of the formula: ##STR00001##
wherein R.sup.1, R.sup.2, and R.sup.3 are as defined herein, wherein the cancer is an autophagy-dependent cancer, in an amount sufficient to induce autophagy in the cell and cause the death of cancer cells. Also disclosed is a method for selectively killing cancer cells in a patient afflicted with cancer, comprising administering to the mammal, wherein the cancer cells are autophagy-dependent cancer cells, in an amount sufficient to induce autophagy in the cells and cause the death of the cancer cells.

Disclosed is method for treating cancer in a mammal, comprising administering to a mammal in need thereof a compound of the formula: ##STR00001##
wherein R.sup.1, R.sup.2, and R.sup.3 are as defined herein, wherein the cancer is an autophagy-dependent cancer, in an amount sufficient to induce autophagy in the cell and cause the death of cancer cells. Also disclosed is a method for selectively killing cancer cells in a patient afflicted with cancer, comprising administering to the mammal, wherein the cancer cells are autophagy-dependent cancer cells, in an amount sufficient to induce autophagy in the cells and cause the death of the cancer cells.

A hydrogen-bonded organic framework (HOF) and a method of making the HOF. The HOF has at least one amine substituted organic linker and at least one carboxylic acid-based organic linker. The HOF is prepared by dissolving the linkers separately in water and mixing the aqueous solutions, without using any organic solvents, additional catalysts, or any other reagents.

A hydrogen-bonded organic framework (HOF) and a method of making the HOF. The HOF has at least one amine substituted organic linker and at least one carboxylic acid-based organic linker. The HOF is prepared by dissolving the linkers separately in water and mixing the aqueous solutions, without using any organic solvents, additional catalysts, or any other reagents.